Oculis’ Post

As the International Myeloma Society (IMS) 2024 annual meeting kicks off in Rio de Janeiro, Brazil, Pharmacy Times will be providing comprehensive coverage of the conference, focusing on the latest advancements in myeloma research and diving into crucial areas like precursor disease, high-risk disease, immunotherapies, novel biomarkers, and more. For a preview of some key interviews at the conference, check out the article below, and stay updated with more exclusive articles and expert interviews by visiting pharmacytimes.com. Link to article: [Don't Miss These Key Interviews and Data at the International Myeloma Society 2024 Congress](https://lnkd.in/ebny934K)

💡 miRNAs in biofluids are promising biomarkers of disease. However, profiling biofluid miRNAs is not without its challenges. Compared to tissues, cells or whole blood, the concentration of miRNAs in cell-free biofluids is super low, making their detection and quantification difficult. We can help you overcome the technical challenges so you can maximize the potential of miRNAs in your biomarker research. Our miRNA-seq Service takes care of every step – from sample prep & QC to library prep & data analysis. Benefit from our expertise and reap the rewards of miRNA profiling in disease research. Learn more ✅ https://lnkd.in/eKbhPCux

🌈 Great News! 😀 Results from a study using Gencurix's companion diagnostic in vitro diagnostic, the Droplex EGFR Mutation Test v2, have been published.  The study reported the results of an updated analysis of the overall survival (OS) and safety of lazertinib 240 mg/day in patients with advanced EGFR T790M-positive NSCLC who had been previously treated with an EGFR-TKI in the LASER201 trial, as well as the results of a circulating tumour DNA (ctDNA) analysis performed to identify potential associations between detected EGFR mutations and patient outcomes. In this study, ctDNA clearance was confirmed by Gencurix's ddPCR-based Droplex EGFR Mutation Test v2, which showed that the 'cleared' group overall had a better prognostic trend in key anti-tumor efficacy endpoints including Objective Response Rate (ORR), Disease Control Rate (DCR), Progression-Free Survival (PFS) and Overall Survival (OS) compared to the 'not cleared' group at baseline, cycle 3 and cycle 5. In particular, significant prognostic superiority was observed for PFS, ORR and DCR at cycle 3. The study's findings highlight the exciting potential of plasma EGFR mutation clearance as a predictor of clinical outcomes in EGFR-mutated NSCLC patients. 👏 Huge congratulations to everyone involved in this impactful research! 🌟 Droplex EGFR Mutation Test v2 : https://lnkd.in/ge7AXdHW #Gencurix #Droplex #NSCLC #Lazertinib #EGFR #ctDNA #CompanionDiagnostics #CancerResearch #PrecisionMedicine #ddPCR

This study by FitzGerald, et al. evaluates the association of serum biomarkers with baseline PsA disease activity, the pharmacodynamic effects of deucravacitinib on biomarker levels, and the relationship between biomarkers and clinical responses to deucravacitinib. The authors found that deucravacitinib impacted the levels of biomarkers in the TYK2 signalling pathway, including IL-23 and Type I IFN, and those related to collagen matrix turnover. You can find the full paper summary on the IMID Forum completely free along with the latest updates in #PsoriaticArthritis https://ow.ly/cfIg50Sn6kT

What does the future of Alzheimer’s disease diagnostics look like? Professor Henrik Zetterberg shares his perspectives and research on developing next-generation diagnostics for Alzheimer’s, article: https://lnkd.in/dYtUaCeq In the clip, Professor Zetterberg discusses quantitative dried plasma microsampling technology - with only a few drops of dried blood from a finger prick, it’s possible to measure all key blood biomarkers for Alzheimer’s disease, by using ultra-sensitive multiplex technology NULISA (Alamar Biosciences, Inc.). These dried blood samples provide results that align with traditional venous blood draws. These biomarkers are stable in room temperature for up to six months. This opens the door to democratizing Alzheimer’s diagnostics by enabling remote testing, even in areas far from labs.   Professor Zetterberg and his team has used Capitainer®B50 and been one of the first users, pre-launch, of our new device Capitainer®SEP10.

https://lnkd.in/gwtPAWge See the data for PBL’s best in class ELISA kits ☝ At 2BScientific Ltd., we offer a range of unique and extensively cited research applications that can effectively improve or enhance your research capability. Today, we present to you PBL Assay Science Assay's VeriKine HS Interferon and Interleukin Elisa kits, designed to accurately measure immune responses and utilized in pre-clinical evaluations. What makes VeriKine HS Elisa a great tool is the unique development of the assays which have been optimised to reliably and accurately measure the lowest levels of endogenous cytokines or interferons that can be otherwise missed in a tissue or cell matrix. This has been possible by testing and approaching the development process by using disease serum and healthy serum for patients with MS, influenza, or other autoimmune diseases. Whether you are an immunologist working in autoimmune disease research, rare disease, or oncology research, PBL’s range of mouse and human Type 1 IFN assays, including the IL-15, IL-22, and IL-3 kits, can be a great tool to elevate your research insights. #2bscientific #hereforyou #assay

IgG4-related disease (IgG4-RD) has complex clinical manifestations ranging from fibrosis and inflammation to deregulated metabolism. The molecular mechanisms underpinning these phenotypes are unclear. To investigate the transcriptomic changes in IgG4-RD patients, we performed transcriptome profiling of B cells isolated from HCs or IgG4-RD patients by using GeneMind GenoLab M sequencer. In this study, by using IgG4-RD patient peripheral blood mononuclear cells (PBMCs), IgG4-RD cell lines and Usp25 knockout mice, we show that ubiquitin-specific protease 25 (USP25) engages in multiple pathways to regulate fibrotic and inflammatory pathways that are characteristic to IgG4-RD. All together, our data suggests that USP25 is associated with fibrosis, inflammation, and metabolism of IgG4-RD patients, which serves as a potential diagnostic and therapeutic target. Click on the link below for further details 💡 #Genomics #Sequencing #NatureCommunication

ME/CFS Research Published 2 – 8 January 2024 There have been nine new ME/CFS studies and twenty-one new Long Covid studies.  Paper two looks at exploring the use of inflammation, immunity and receptor-based biomarkers for evaluating the progression of ME/CFS. This is a follow-up study from this research group who have previously reported that antibodies to beta2-adrenergic (anti-β2AdR) and muscarinic acetylcholine (anti-M4) receptors demonstrate sensitivity to the progression of ME/CFS (Gravelsina et al., 2022). https://lnkd.in/eZ4k6qAA #pwME #MECFS #MyalgicE #MyalgicEncephalomyelitis #LongCovid #PostCovid #Research 

Make sure to register for our upcoming webinar: Tuesday, June 18th 11:00 AM-12 PM EDT The Balancing Act Between Number Of Colors And Data Quality: Lessons Learned From Human Memory T Cells Speaker: Maria C Jaimes, MD, VP Scientific Commercialization, Cytek Biosciences, Inc In this webinar, we will discuss the importance of balancing quality and quantity when optimizing robust multiparametric assays, empowered by Cytek’s Full Spectrum Profiling™ (FSP™) technology. The increase in the number of simultaneously evaluated markers requires a careful selection of highly overlapping dyes to avoid introducing detrimental spread and compromising population resolution, thus, shifting the focus from quantity to quality according to experimental needs. We will present the strategy used in the development of a high-quality human 45-color panel, built on Cytek’s OMIP-069 publication, which allows for comprehensive characterization of major cell lineages present in circulation including T cells, γδ T cells, NKT-like cells, B cells, NK cells, monocytes, basophils, dendritic cells, and ILCs, as well as more in-depth characterization of memory T cells. We will discuss the steps taken to ensure that each marker in the panel was optimally resolved and that data was accurately interpreted. Furthermore, we will discuss how this panel can be effectively used for cell sorting on instruments with a similar optical layout to achieve the same level of resolution. We demonstrate how functional evaluation of sorted specific rare cell subsets exhibited significantly different patterns of immunological responses to stimulation, supporting functional and phenotypic differences within the T cell memory subsets. In summary, the combination of FSP technology and careful assay design and optimization results in high resolution multiparametric assays. This approach offers the opportunity to fully characterize immunological profiles present in peripheral blood in the context of infectious diseases, autoimmunity, neurodegeneration, immunotherapy, and biomarker discovery. Click here to register: https://lnkd.in/e7j-kv9f #flowcytometry #immunology #OMIP

Quantitative mass spectrometry-based proteomics is pivotal in the discovery and validation of biomarkers. For enthusiasts aiming to harness the potential of proteomes in comprehending disease pathologies and advancing precise blood-based diagnostic tests, the free webinar below sponsored by Bruker, might pique your interest, especially if you're unable to attend conferences. #precisionmedicine #bruker #massspectrometry #proteomics High-Throughput Plasma Profiling for Enhanced Biomarker Discovery | Technology Networks